BRAF and melanoma: Although treatment with BRAF/MEK combinatory regimens such as dabrafenib + trametinib, vemurafenib + cobimetinib, and encorafenib + binimetinib, as well as with immunomodulators such as pembrolizumab and iplimumab, have shown some efficacy in V600K-mutant melanoma, evidence is not strong enough to make any formal first-line treatment recommendation for melanoma patients with the V600K mutation.